Meeting
2023 ASCO Annual Meeting
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.
Authors
Yan Xu
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Yan Xu , James Chih-Hsin Yang , Chao-Hua Chiu , Ping-Chih Hsu , Paul Mitchell , Chia lun Chang , Tom John , Lyudmila Bazhenova , Tae Min Kim , Ching Wan Yip , Mengzhao Wang , Pasi A. Janne , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03974022, NCT05559645
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9073)
DOI
10.1200/JCO.2023.41.16_suppl.9073
Abstract #
9073
Poster Bd #
61
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
First Author: Pasi A. Janne
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2023 ASCO Annual Meeting
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.
First Author: James Chih-Hsin Yang
Poster
2022 ASCO Annual Meeting
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.
First Author: Gongyan Chen